Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7081345 | 0.80 | MAPT (0.47) | LMNAALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL2480440 | 0.78 | HTT (0.49) | LMNAALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL2825270 | 0.77 | CYP19A1 (0.35) | — | |
| SCHEMBL960742 | 0.74 | ALDH1A1 (0.54) | LMNAALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL1038330 | 0.74 | ALDH1A1 (0.54) | LMNAALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL1828659 | 0.74 | GRIA1 (0.39) | ALDH1A1MAPTMEN1KMT2AVCAM1 | |
| SCHEMBL4593210 | 0.74 | ALDH1A1 (0.48) | LMNAALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL3156146 | 0.74 | LMNA (0.57) | LMNAALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL11775775 | 0.73 | CYP19A1 (0.43) | ALDH1A1MAPTMEN1KMT2AHTT | |
| SCHEMBL4592691 | 0.73 | ALDH1A1 (0.47) | LMNAALDH1A1GAASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432256-B2 | Substitued imidazo [1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1828194-B1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | EP | disclosed |
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA3, GABRA5, GABRA1 | LMNA 3773/4885ALDH1A1 619/4885GAA 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.